Literature DB >> 32557836

Undifferentiated endometrial carcinoma arising in the background of high-grade endometrial carcinoma - Expanding the definition of dedifferentiated endometrial carcinoma.

Aurelia Busca1, Carlos Parra-Herran2,3, Sharon Nofech-Mozes2,3, Bojana Djordjevic2,3, Nadia Ismiil2,3, Mathew Cesari3,4, Marisa R Nucci5, Jelena Mirkovic2,3.   

Abstract

Dedifferentiated endometrial adenocarcinoma (DEC) is defined by the coexistence of undifferentiated carcinoma with low-grade (FIGO grade 1 or 2) endometrioid carcinoma. Few cases of DEC arising in the background of high-grade carcinoma (DEC-HG) have been reported, however, this phenomenon is poorly characterized. In this study we describe the morphologic, immunohistochemical and clinico-pathologic characteristics of DEC-HG. 18 DECs were diagnosed at our institution between 2008-2019, and in 11 (61%), the undifferentiated component was associated with high-grade carcinoma (8 endometrioid FIGO grade 3, 2 with ambiguous features, 1 serous). The remaining 7 (39%) represented DEC-LG (3 FIGO grade 1 and 4 FIGO grade 2). 7/11 (64%) patients with DEC-HG presented with advanced stage (FIGO stage III/IV), whereas most with DEC-LG (6/7, 86%) were stage I. On follow up, 2 patients in the DEC-HG group died of disease and 2 had progressive disease within 2 months of surgery. There was only one recurrence in the DEC-LG, 6 months post-surgery. The DEC component in both groups showed similar morphology and immunophenotype, with predominantly focal or complete loss of expression of pan-keratin, EMA, E-cadherin, CK8/18, PAX8 and ER. The DEC component in the DEC-HG group had wild-type p53 expression in 8/11 (73%) cases, loss of MLH1 and PMS2 in 6/11 (55%) and loss of SMARCA4 in 3/9 (33%). Although numbers are small, we show that DEC-HG is a previously under-recognized phenomenon, with morphologic and immunophenotypic similarities to DEC-LG, which supports expanding the definition of DEC to include DEC-HG. DEC-HG may be more aggressive than DEC-LG.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  dedifferentiated carcinoma; high grade endometrial carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32557836     DOI: 10.1111/his.14186

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  4 in total

Review 1.  Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.

Authors:  Antonio Travaglino; Antonio Raffone; Diego Raimondo; Damiano Arciuolo; Giuseppe Angelico; Michele Valente; Giulia Scaglione; Nicoletta D'alessandris; Paolo Casadio; Frediano Inzani; Antonio Mollo; Angela Santoro; Renato Seracchioli; Gian Franco Zannoni
Journal:  Int J Gynaecol Obstet       Date:  2021-10-11       Impact factor: 4.447

Review 2.  Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice.

Authors:  Hsiu-Jung Tung; Ren-Chin Wu; Chiao-Yun Lin; Chyong-Huey Lai
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

Review 3.  New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.

Authors:  Angela Santoro; Giuseppe Angelico; Antonio Travaglino; Frediano Inzani; Damiano Arciuolo; Michele Valente; Nicoletta D'Alessandris; Giulia Scaglione; Vincenzo Fiorentino; Antonio Raffone; Gian Franco Zannoni
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

4.  SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.

Authors:  Martin Köbel; Cheng-Han Lee; Basile Tessier-Cloutier; Mackenzie Coatham; Mark Carey; Gregg S Nelson; Sarah Hamilton; Amy Lum; Robert A Soslow; Colin Jr Stewart; Lynne M Postovit
Journal:  J Pathol Clin Res       Date:  2020-10-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.